Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

AI Briefing

• – Novartis to acquire PI3Kα inhibitor SNV4818 for breast cancer treatment
• – Acquisition strengthens Novartis' pipeline with next-generation cancer therapy
• – Partnership aims to explore treatment of HR+/HER2- breast cancer and other solid tumor indications